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Abstract
Background: There is overwhelming evidence that in vitro three-dimensional tumor cell cultures more accurately
reflect the complex in vivo microenvironment than simple two-dimensional cell monolayers, not least with respect
to gene expression profiles, signaling pathway activity and drug sensitivity. However, most currently available three-
dimensional techniques are time consuming and/or lack reproducibility; thus standardized and rapid protocols are
urgently needed.
Results: To address this requirement, we have developed a versatile toolkit of reproducible three-dimensional
tumor spheroid models for dynamic, automated, quantitative imaging and analysis that are compatible with
routine high-throughput preclinical studies. Not only do these microplate methods measure three-dimensional
tumor growth, but they have also been significantly enhanced to facilitate a range of functional assays
exemplifying additional key hallmarks of cancer, namely cell motility and matrix invasion. Moreover, mutual tissue
invasion and angiogenesis is accommodated by coculturing tumor spheroids with murine embryoid bodies within
which angiogenic differentiation occurs. Highly malignant human tumor cells were selected to exemplify
therapeutic effects of three specific molecularly-targeted agents: PI-103 (phosphatidylinositol-3-kinase (PI3K)-
mammalian target of rapamycin (mTOR) inhibitor), 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (heat
shock protein 90 (HSP90) inhibitor) and CCT130234 (in-house phospholipase C (PLC)g inhibitor). Fully automated
analysis using a Celigo cytometer was validated for tumor spheroid growth and invasion against standard image
analysis techniques, with excellent reproducibility and significantly increased throughput. In addition, we
discovered key differential sensitivities to targeted agents between two-dimensional and three-dimensional
cultures, and also demonstrated enhanced potency of some agents against cell migration/invasion compared with
proliferation, suggesting their preferential utility in metastatic disease.
Conclusions: We have established and validated a suite of highly reproducible tumor microplate three-
dimensional functional assays to enhance the biological relevance of early preclinical cancer studies. We believe
these assays will increase the translational predictive value of in vitro drug evaluation studies and reduce the need
for in vivo studies by more effective triaging of compounds.
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The preclinical validation process in cancer drug discov-
ery generally comprises a series of primary biochemical
and cell-based assays, followed by evaluation in animal
tumor models. However, there is a high rate of attrition
and fewer than 10% of candidates identified by high-
throughput (HT) screening become licensed drugs [1].
Standard two-dimensional cell cultures for testing effects
of anticancer agents are simple and convenient, but pre-
sent significant limitations in reproducing the complex-
ity and pathophysiology of in vivo tumor tissue [2-8].
Three-dimensional culture systems are of increasing
interest in cancer research since tissue architecture and
the extracellular matrix (ECM) significantly influence
tumor cell responses to microenvironmental signals. For
example, inhibition of b1-integrin on breast tumor cells
reverted their morphological and functional features to
a normal epithelial phenotype, but only in three dimen-
sions [9]. This and many other studies have highlighted
significant differences between two-dimensional and
three-dimensional cultures, with the latter reflecting bet-
ter the in vivo tumor microenvironment in terms of cel-
lular heterogeneity, nutrient and oxygen gradients, cell-
cell interactions, matrix deposition and gene expression
profiles [5,6,8-11]. To model solid tumors more effec-
tively, several three-dimensional culture systems have
been established: whole perfused organs, tissue explants,
scaffold/microcarrier-based cultures, hollow-fiber bior-
eactors, organotypic cultures (multicellular spheroids
and cellular multilayers) and gel/matrix-based cultures
[3,4,12-15]. Of these, the multicellular tumor spheroid
model is the best characterized and most widely used.
Tumor spheroids are heterogeneous cellular aggregates
that, when greater than 500 μm diameter, are frequently
characterized by hypoxic regions and necrotic centers
[16,17]. Three-dimensional spheroids are therefore con-
sidered valid models to recapitulate features of tumor
microregions, intervascular domains or micrometastases
[10,12]. Sutherland et al. first applied this technique in
cancer research [18]. Since then, several methods have
been used to generate tumor spheroids: spontaneous
aggregation [19,20], spinner flasks [21], rotary cell culture
systems [3,22], poly-2-hydroxyethyl methacrylate (poly-
Hema)-coated plates [23,24], hanging drops [25], liquid
overlay on agar [26-28], low binding plates [29,30], gel/
matrix-based culture [31], polymeric scaffolds [11] or
micropatterned plates [32,33].
Each method has advantages and limitations [3,13] but
simple, standardized and rapid protocols appropriate for
routine preclinical drug development studies within aca-
demic or pharmaceutical labs are lacking. Furthermore,
there is an appreciation that the next generation of
anticancer drugs will need to address aspects of the
malignant phenotype beyond cell proliferation if we are
to effectively address disseminated disease. We have
therefore developed a complete suite of in vitro three-
dimensional spheroid-based assays for measuring tumor
growth, migration, invasion and tumor angiogenesis
that, combined with new technologies of automated
imaging and analysis, demonstrate applicability in rela-
tively high-throughput formats.
We initially screened and classified a diverse collection
of human tumor cell lines for their ability to form
spheroids. For more detailed assay exemplification,
selected lines representing highly malignant human
tumors and characterized by an optimal three-dimen-
sional structure were used. The following report is
divided into two sections: a description of the establish-
ment of the suite of three-dimensional spheroid growth
and functional assays, and an exemplification of the uti-
lity of the assays to measure inhibitory effects of mole-
cularly targeted agents. Inhibitors of heat shock protein
90 (HSP90) chaperone (17-N-allylamino-17-demethoxy-
geldanamycin (17-AAG)), phosphatidylinositol-3-kinase
(PI3K)-mammalian target of rapamycin (mTOR) (PI-
103) and phospholipase C (PLC)g (CCT130234), repre-
senting a variety of validated targets in tumor growth,
invasion and angiogenesis [34-37], were selected for eva-
luation. We believe that these assays will contribute to
increased utility and predictive value of preclinical drug
discovery studies.
Results
Establishment of three-dimensional spheroid-based
assays
Rapid generation of reproducibly sized tumor spheroids
and automated growth kinetic analyses
To deploy three-dimensional cultures in cancer drug
discovery and target validation, we established a standar-
dized microplate method with the following desirable
characteristics: (i) 96-well suspension culture; (ii) a sin-
gle spheroid/well, centered for ease of optical imaging;
(iii) high reproducibility; (iv) simple harvesting for
further analysis; (v) fully automated imaging and quanti-
tative analysis.
We used ultra-low attachment (ULA) 96-well round-
bottomed plates that, in contrast to standard methods,
do not require coating to prevent cell adhesion. Tumor
cell suspensions formed a three-dimensional structure
within 24 to 48 h. The well shape promotes the forma-
tion of single, centrally located spheroids of reproducible
size (Figure 1a). Optimal seeding densities were estab-
lished such that tumor spheroids for every cell line
tested (regardless of their proliferative potential and cell
cycle time) fell within a size range of 300 to 500 μmi n
diameter on day 4, considered appropriate for initiating
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Page 2 of 20Figure 1 High throughput (HT) standardized method for generation, imaging and analysis of tumor spheroids. (a) Ultra-low attachment
(ULA) 96-well round-bottomed plates were used to generate suspension cultures of reproducibly sized, single spheroids in each well. (b) Fully
automated imaging and analysis was carried out on a Celigo cytometer using the Colony Counting Embryoid Body application with 1/16 field of
view/well. A screen print shows reproducibly sized U-87 MG spheroids across the plate and detail of the segmentation analysis around the
spheroid. Scale bar: 500 μm. (c) U-87 MG tumor spheroid growth curve. Values are means ± SD (n = 6). Representative images obtained on
Celigo for each timepoint are shown. Scale bar 500 μm. (d) Frequency plots of 4-day U-87 MG spheroid volume (μm
3 ×1 0
7) across a plate
containing 60 spheroids.
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replacing 50% of the medium on days 4, 7, 10 and 12.
For rapid, routine imaging and analysis of tumor spher-
oids, we utilized a Celigo™ cytometer (Cyntellect Inc,
San Diego, CA, USA; http://www.cyntellect.com/content/
products/celigo/index.html) (Figure 1b), which is a
benchtop in situ cellular analysis system providing high
quality, full or partial images of wells using brightfield or
fluorescent illumination. Images were acquired and ana-
lyzed using the Colony Counting Embryoid Body (EB)
application that identifies and counts individual three-
dimensional structures (EBs or spheroids) and small clus-
ters of cells. With our centrally located spheroids and by
selecting 1/16 field of view/well (Figure 1b) the Celigo
cytometer scans a ULA 96-well plate in 8 minutes, allow-
ing fast, automated multiparametric analysis including
measurements of spheroid diameter, perimeter and area.
This application allows the generation of image segmen-
tation around the spheroid, as shown in Figure 1b.
Images are acquired at intervals and growth curves are
rapidly and easily generated, showing linear volume
increases up to 14 days following cell seeding. An exam-
ple using U-87 MG glioblastoma is shown in Figure 1c.
Small standard deviations demonstrate the reproducibil-
ity and robustness of the method.
We tested 40 tumor cell lines in total (Table 1) and
classified spheroids according to their morphology,
extending the original Ivascu classification [23] as fol-
lows: tight spheroids (for example, SF188 glioblastoma):
tight, spherical and regular; compact aggregates (for
example, MDA-MB-231 breast carcinoma): acceptable
for three-dimensional studies but less regular; loose
aggregates (for example, IGROV-1 ovarian carcinoma):
irregular, friable aggregates (Table 1 and Additional
file 1). The three-dimensional structure of compact and
loose spheroids can be improved by the addition of
Matrigel™ (BD Biosciences, Oxford, England) at the time
of initiation, extending the range of tumor cells suitable
for further study (Additional file 1).
To demonstrate the reproducibility in spheroid size, the
coefficient of variation (CV) of spheroid volumes on day 4
was determined for selected highly malignant tumor cell
lines that form tight spheroids. The intraplate CV was
5.53% to 7.15% for U-87 MG (adult glioblastoma), 4.97%
to 10.57% for KNS42 (pediatric glioblastoma) and 7.59%
to 10.59% for LICR-LON-HN4 (laryngeal squamous cell
carcinoma). The interplate CV gave values of 17.88% for
U-87 MG, 11.21% for KNS42 and 10.75% for LICR-LON-
HN4 (n = 3, tested over three different batches of plates).
Furthermore the spheroid volume distribution follows a
Gaussian distribution (U-87 MG, Figure 1d). Similar
results were obtained for other cell lines such as KNS42
and LICR-LON-HN4 (data not shown).
In order to compare our system to a standard conven-
tional method, U-87 MG spheroids were initiated and
cultured in parallel on agar-coated 96-well flat-bottomed
plates [26] and in ULA 96-well round-bottomed plates
(Figure 2). The agar-coated plates, unlike the ULA plates,
proved unsuitable for automated image analysis on the
Celigo cytometer (probably due to variations in the thick-
ness of agar in each well). Thus, images were obtained at
intervals using an Olympus IX 70 (Olympus Microscopy,
Southend-on-SeaEssex, UK) inverted microscope. Analy-
sis was carried out using Image-Pro Plus Analyzer soft-
ware (Media Cybernetics, Inc., Bethesda, MD, USA;
http://www.mediacy.com/index.aspx?page=IPP). Repro-
ducibly sized spheroids (a single spheroid/well) were
obtained in each system, with ULA spheroids growing to
slightly larger sizes than the agar-based spheroids but
both growth curves reached a plateau at around day 14
(Figure 2a).
Spheroids grown on ULA plates showed a more com-
pact structure than those on agar-coated plates (Figures
2b, 3a, b and Additional file 2a). In both cases, (suspen-
sion and agar plated) larger U-87 MG spheroids develop
a gradient of proliferation as measured by Ki-67 staining
[10] and a more intense glucose transporter 1 (GLUT-1)
staining (Figure 3a, b) that correlates with tumor
hypoxia [38]. Central necrosis was not evident in U-87
MG spheroids over this observation period although
was seen in HCT 116 spheroids (data not shown). Thus,
overall our system compares closely with convention-
ally-generated spheroids, but with the advantage that
automated analysis and retrieval of spheroids for mole-
cular analysis is more easily achieved with suspension
cultures in ULA plates. U-87 MG spheroids were also
grown on poly-Hema-coated 24-well plates and in a
Rotary Cell Culture System (RCCS; Synthecon, El Rio
Houston, TX, USA; http://www.synthecon.com/) (Addi-
tional file 2c) but multiple non-reproducibly sized
s p h e r o i d sw e r ef o r m e da n dh e n c et h e s em e t h o d sw e r e
not pursued further.
Three-dimensional tumor spheroid functional assays
Another major advantage of our approach is its conveni-
ent extension to additional three-dimensional functional
assays to address important cellular processes in tumor
progression: (i) migration on extracellular matrix pro-
teins (ECM), (ii) invasion into Matrigel and (iii) simulta-
neous tissue invasion/angiogenesis (by coculture with
EBs) (Figures 4 and 5).
Migration on matrix protein
We utilized a tumor spheroid-based migration assay that
resembles tumor cell dissemination from a solid micro-
tumor or micrometastasis in terms of engagement of
host stromal matrix proteins with characteristics that
differ from isolated cells [39-41]. The same type of assay
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and with more time-consuming methods for generation
of tumor spheroids [42-44]. Wes u c c e s s f u l l ym o d i f i e d
the assay for HT format by rapidly transferring tumor
spheroids generated in ULA round-bottomed plates into
gelatin-coated flat-bottomed 96-well plates (a single
spheroid/well) using a multichannel pipette (Figure 4a).
Within a few hours, tumor cells disseminate from the
spheroid over the coated surface [44] and migration is
recorded at intervals up to 72 h. Images can be obtained
using an inverted microscope and analysis performed
using Image-Pro Analyzer software by manually record-
ing the leading edge of the migrating cells, which
enables the software to calculate the area covered. This
Table 1 Tumor cell lines
Cell line Tumor type Three-dimensional morphology Supplier Medium
U-87 MG GBM (adult) T ATCC 1
A172 GBM (adult) T ATCC 1
SF126 GBM (adult) T JCRB 1
LN-229 GBM (adult) T ATCC 1
SF268 GBM (adult) C NCI repository 1
SF188 GBM (pediatric) T Bax, 2009 [56] 2
KNS42 GBM (pediatric) T Bax, 2009 [56] 2
RES186 Astrocytoma (pediatric) T Bax, 2009 [56] 2
RES259 Astrocytoma (pediatric) T Bax, 2009 [56] 2
UW479 Astrocytoma (pediatric) L Bax, 2009 [56] 2
WT-CLS1 Wilm’s kidney T CRUK Cell Line Services 1
WiT49 Wilm’s kidney T Dr H Yeger, Hospital for Sick Children, Toronto 1
IMR-32 Neuroblastoma T ATCC 1
SH-SY5Y Neuroblastoma C Dr L Chesler, ICR 3
KELLY Neuroblastoma C Dr L Chesler, ICR 3
SHEP Neuroblastoma T Dr L Chesler, ICR 3
U-2 0S Osteosarcoma C ATCC 1
Detroit 562 SCC (pharynx) T ATCC 1
CAL 27 SCC (tongue) T ATCC 1
PECA/CA-PJ34 SCC (basaloid) T ECACC 4
PE/CA-PJ41
a SCC (oral) C ECACC 4
SIHN-011A SCC (tongue) C O-charoenrat, 2001 [57] 1
LICR-LON-HN4 SCC (larynx) T Easty, 1981 [58] 1
SK-Mel-5 Melanoma L ATCC 1
NCI-H23 Lung C ATCC 3
MDA-MB-231
a Breast C ATCC 1
MCF-7 Breast C ATCC 1
DLD-1 Colon T ATCC 1
HCT 116 Colon T ATCC 1
RKO
a Colon L ATCC 1
HT-29 Colon T ATCC 1
SW620
a Colon L ATCC 1
PC-3
a Prostate L ATCC 3
A2780 Ovarian L ECACC 3
IGROV-1
a Ovarian L CRUK Cell Line Services 3
SK-OV-3
a Ovarian L ATCC 3
PANC-1
a Pancreatic C ATCC 1
MIA PaCa-2 Pancreatic L ATCC 1
Hep G2 Hepatocellular C ATCC 5
Hep 3B Hepatocellular C ATCC 5
aCell lines in which three-dimensional structure is improved by addition of Matrigel at spheroid initiation.
Medium: 1 = DMEM; 2 = DMEM:F12; 3 = RPMI; 4 = Iscove’s Modified Dulbecco’s Medium; 5 = Eagle’s Minimum Essential Medium.
ATCC = American Type Culture Collection; C = compact aggregate; ECACC = European Collection of Cell Cultures; GBM = glioblastoma; JCRB = Japanese
Collection of Research Bioresources; L = loose aggregate; SCC = squamous cell carcinoma; T = tight spheroid
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different cell migration patterns (Figure 4b). For exam-
ple, U-87 MG cells show rapid, single cell dispersal
resembling typical amoeboid migration [45,46]. In con-
trast, KNS42 cells move slowly and collectively in a
radial pattern, reflecting a more mesenchymal pheno-
type [45,46] (Additional files 3 and 4).
Three-dimensional invasion into Matrigel
To measure three-dimensional tumor invasion (Figure 4c),
spheroids are initiated as described above and on day 4
Matrigel is added to the wells. This provides a semisolid
gel-like matrix into which cells extend invadopodia
[47,48]; these processes contribute to cell movement and
also matrix degradation via localized proteolysis [47].
Within a few hours, the invadopodia are apparent and
invasion is monitored at intervals over 72 h. Image analysis
is performed on a Celigo cytometer by using the Cell
Counting Confluence application, which determines the
area occupied by individual cells or cell clusters, identified
by image segmentation around the invading cells (Figure
4d). The central location of each spheroid allows rapid
and automated image analysis and by selecting 1/16 field
of view per well the scan is completed within 10 minutes/
plate. Alternatively, images can be obtained using an
inverted microscope and analysis is performed as
described for the migration. Microscopy additionally pro-
vides detailed images of the invading cell protrusions as
shown in Figure 4e.
Tissue invasion and angiogenesis
The angiogenic switch is a critical step in tumor progres-
sion [49]. We modified a confrontation culture assay of
spheroids and EBs [21] to mimic simultaneous tissue
invasion and tumor angiogenesis in vitro.W i t ht h e i r
complex cellular heterogeneity, including differentiated
endothelial cells, EBs represent a true tissue environment.
The method is a simple three-step procedure: (1) culture
of mouse embryonic stem cells (mESCs) (Figure 5a); (2)
differentiation of mESCs into EBs (Figure 5b, c); (3)
coculture of spheroids and EBs (Figure 5d, e). To opti-
mize the assay for future HT target validation and/or
drug evaluation studies, EBs were grown in ULA 96-well
round-bottomed plates rather than Petri dishes [50] or
spinner flasks [21], increasing EB reproducibility and sig-
nificantly reducing the time needed for assay set-up.
Fully automated cytometer image analysis shows linear
growth curves with increased variability only during later
stages of maturation (Figure 5b). Consistent with pre-
vious reports [21,50], we demonstrated endothelial differ-
entiation by CD34 staining (Figure 5d).
Our confrontation culture is a significant enhancement
of previous assays, since day 4 tumor spheroids are trans-
ferred directly into wells containing day 5 EBs (when
endothelial cell differentiation begins [21]) and the system
allows real-time analysis of subsequent interactions.
Representative images from the Celigo cytometer show
two distinct bodies at confrontation, with the U-87 MG
spheroid identified by green fluorescent protein (GFP)
fluorescence. The mutual integration process is complete
within 50 to 60 h, as shown in the merged brightfield and
fluorescent images (Figure 5e). Confrontation cultures can
also be imaged by microscopy, allowing timelapse studies
(Figure 5f and Additional file 5). Treatment with 17-AAG
was shown to inhibit U-87 MG EB tissue invasion (Addi-
tional file 6). Tumor-stimulated angiogenesis is illustrated
Figure 2 Tumor spheroid growth: ultra-low attachment (ULA) 96-well round-bottomed plates vs agar-coated 96-well flat-bottomed
plates. (a) ULA 96-well round-bottomed plates and agar-coated 96-well flat-bottomed plates were used to generate U-87 MG spheroids (a
single spheroid per well). Starting from day 4 post initiation, images were obtained at intervals using an inverted microscope. Analysis was
carried out using Image-Pro Analyzer software and growth curves were obtained. Values are means ± SD (n = 16 spheroids/timepoint; a
representative result of two independent experiments is shown). (b) Representative images of U-87 MG spheroids grown on ULA plates or on
agar-coated plates at the indicated timepoints. Scale bar: 100 μm.
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Page 6 of 20Figure 3 Comparison of U-87 MG spheroids grown on ultra-low attachment (ULA) plates or agar: immunostaining. Hematoxylin and
eosin (H&E), glucose transporter 1 (GLUT-1) or Ki67 antibody staining of sections of U-87 MG spheroids grown for 4, 7 and 14 days on (a) ULA
96-well round-bottomed plates or (b) agar-coated 96-well flat-bottomed plates. Spheroids on (a) ULA plates show a tighter structure than
spheroids grown on (b) agar, across all timepoints. H&E staining is homogeneous, while there was a gradient of proliferation (Ki67) in larger
spheroids (day 14). A more intense staining of GLUT-1 was observed concomitantly with the age of the spheroids, irrespective of the means of
generation (a, b). Scale bar 100: μm.
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Page 7 of 20Figure 4 Three-dimensional tumor spheroid-based functional assays: migration and invasion. (a) Tumor spheroid-based migration is
illustrated in a cartoon: a single day 4 tumor spheroid was transferred to each well of extracellular matrix (ECM)-coated 96-well flat-bottomed
plate using a multichannel pipette. (b) Representative brightfield images of U-87 MG and KNS42 cell migration (48 h) are shown. (c) Tumor
spheroid invasion into Matrigel is illustrated in a cartoon: a single tumor spheroid per well was embedded in Matrigel. (d) Representative images
of a typical U-87 MG ‘starburst’ invasion pattern obtained with a Celigo cytometer. The Cell Counting Confluence application (1/16 field of view/
well) produces a segmentation analysis that identifies the area occupied by invading cells. (e) Representative images obtained using a
conventional inverted microscope show the U-87 MG invasion at low magnification and details of invadopodia advancing into the matrix shown
at higher magnification. Scale bar: 100 μm.
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Page 8 of 20Figure 5 Mouse embryonic stem cell (mESC) differentiation into embryoid bodies (EBs) and confrontation culture with tumor
spheroids. (a) R1 mES cells grown as colonies on feeder layers of mouse embryonic fibroblasts (MEFs) in the presence of leukemia inhibitory
factor (LIF). (b) Suspension growth of mESCs on ultra-low attachment (ULA) 96-well round-bottomed plates allows spontaneous differentiation
into EBs. Representative images of EBs are shown. Scale bar: 500 μm. (c) EB growth curve, determined by automated imaging analysis on a
Celigo cytometer, (n = 12 EBs/timepoint). Values are mean ± SD. (d) CD34 staining of day 12 EBs shows endothelial differentiation (brown
staining). Scale bar: 100 μm (left) or 50 μm (right). (e) Confrontation culture of green fluorescent protein (GFP)-transduced U-87 MG tumor
spheroid (TS) and EB is represented in a cartoon on the left: a single TS and EB are cocultured in each well of a ULA 96-well round-bottomed
plate. Representative images are shown at t0 and 55 h. Images were obtained on a Celigo cytometer. Scale bar: 500 μm. (f) Selected frames of a
timelapse study show mutual invasion and coalescence of the two organoids. Images were obtained on an inverted microscope. Scale bar:
500 μm.
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Page 9 of 20by immunohistochemical staining of EB-derived endothe-
lial cells within tumor spheroids (Additional file 7).
Together, these assays provide a suite of novel, com-
plementary functional assays with immediate relevance
to cancer progression and enabling rapid evaluation of
new therapeutic agents, as exemplified below.
Exemplification of the methods for evaluation of
anticancer agents
Evaluation of effects of signaling inhibitors on cell viability
in three-dimensional vs two-dimensional cultures
In order to evaluate responsiveness in our suite of tumor
spheroid assays, we first compared the sensitivity of cells
in three-dimensional vs two-dimensional cultures to
selected compounds using the CellTiter Glo cell viability
assay which is quick, easy and reproducible. This was vali-
dated in pilot studies that determined optimum incubation
time of the reagents, and showed good correlation
between spheroid size and luminescent emission as well as
spheroid size and the number of viable cells per spheroid
(Additional file 8).
MDA-MB-231, U-87 MG, KNS42 and LICR-LON-
HN4 cells were treated with 17-AAG (HSP90 chaperone
i n h i b i t o r ) ,P I - 1 0 3( P I 3k inase/mTOR inhibitor) or
CCT130234 (PLCg inhibitor) in two-dimensional and
three-dimensional cultures, and concentrations inhibiting
cell viability by 50% (GI50) were determined after 72 h.
Tumor cells were generally less sensitive to compounds
in three-dimensional than in two-dimensional cultures
(Table 2 and Additional file 9). MDA-MB-231 P (parental
variant) cells treated with 17-AAG showed a clear shift of
the cell survival curve, resulting in a higher GI50 in three
dimensions (Additional file 10a). This could reflect
reduced compound access or pathophysiological differ-
ences in the response of hypox i co rm o r es l o w l yc y c l i n g
cells under these conditions (as in solid tumors in vivo
[51]). This was not the case with CCT130234 in three
dimensions (Additional file 10b). Furthermore, both U-
87 MG and KNS42 were more sensitive in three dimen-
sions to PI-103 (Table 2 and Additional file 9) confirming
previous reports of increased sensitivity to PI3 kinase
inhibitors in three dimensions [34]. This highlights the
importance of accurately evaluating drug responses
under appropriate conditions in vitro in order to avoid
overestimating or underestimating the effect of com-
pounds prior to in vivo studies.
Tumor spheroid growth inhibition with 17-AAG and PI-103
For evaluation of the effects of molecularly targeted
agents on three-dimensional tumor growth kinetics, 4-
day-old spheroids (for example, U-87 MG) were treated
with compounds for 72 h. Medium replenishment and
imaging was performed as shown on the schematic pro-
tocol in Figure 6a. 17-AAG and PI-103 induced concen-
tration-dependent growth inhibition (Figure 6b, d for
17-AAG and Figure 6e, g for PI-103).
This assay allows dynamic effects of compounds to be
measured over time; a significant advantage compared to
standard endpoint assays in two dimensions. Moreover, it
can demonstrate whether a single administration of the
agent is sufficient to inhibit spheroid growth or induce
‘regression’ as shown in Figure 6b. Note the excellent
reproducibility of the spheroids on each plate across the
six replicates/conditions (Figure 6c, f) and the Gaussian
distribution of the spheroid volume that is maintained
over the observation period, not only in controls but also
in treated U-87 MG spheroids (Additional file 11).
Tumor spheroid growth in this system is thus character-
ized by small standard deviations, which facilitate quanti-
tative analysis and the ability to sensitively discern
statistically significant differences between test and con-
trol conditions. Similar results of dose response inhibi-
tion on tumor spheroid growth were obtained with
further cell lines, for example, KNS42 and LICR-LON-
Table 2 Concentration inhibiting cell viability by 50% (GI50) values for selected tumor cell lines treated with 17-N-
allylamino-17-demethoxygeldanamycin (17-AAG), PI-103 or CCT130234
Inhibitor (μM) Cell line Two-dimensional Three-dimensional
17-AAG: U-87 MG 0.43 ± 0.13 0.82 ± 0.16
KNS42 18.02 ± 6.42 81.43 ± 1.60
MDA-MB-231 P 2.47 ± 0.83 2.33 ± 0.33
MDA-MB-231 M 0.75 ± 0.10 6.19 ± 0.50
LICR-LON-HN4 0.07 ± 0.06 0.38 ± 0.11
PI-103: U-87 MG 0.49 ± 0.13 0.16 ± 0.03
KNS42 2.15 ± 1.20 0.72 ± 0.34
MDA-MB-231 P 2.39 ± 0.69 > 100
CCT130234: U-87 MG 9.10 ± 1.13 16.40 ± 0.14
MDA-MB-231 P 11.5 ± 3.32 8.50 ± 0.62
Cells cultured in two dimensions and three dimensions were treated with compounds for 72 h. A CellTiter Glo
® viability assay was performed and GI50 values
were obtained. Values are means ± SD of the studies reported in Additional file 10 (apart from MDA-MB-231 P that when treated with PI-103 over the
concentration range tested, did not achieve a GI50).
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Page 10 of 20Figure 6 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) and PI-103 concentration-dependent inhibition of tumor spheroid
growth. (a) Schematic illustration of tumor spheroid growth kinetics and compound treatment procedures. Spheroids were initiated on day 0,
treated with compound or vehicle on day 4, and 50% medium replenishment performed on days 7, 10 and 12. A Celigo cytometer was used for
automated imaging and analysis. (b-g) Day 4 U-87 MG spheroids were treated with 17-AAG (heat shock protein 90 (HSP90) inhibitor) or PI-103
(phosphatidylinositol-3-kinase (PI3K)- mammalian target of rapamycin (mTOR) inhibitor) with 1:2 serial dilutions (final concentrations 0 to 4 μM
for 17-AAG and 0 to 2 μM for PI-103). Control spheroids were treated with vehicle. Values are means ± SD (n = 6) and a representative of three
separate experiments for each agent is shown. Student t test with Welch’s correction was performed relative to the 14-day values: (b) vehicle
controls vs 0.015 and 0.031 μM not significant; vs 0.062 μM P < 0.01; vs all higher concentrations P < 0.001; (e) vehicle controls vs 0.007 to 0.031
μM not significant; vs all higher concentrations P < 0.001. Screen prints of plates for (c) 17-AAG or (f) PI-103, corresponding to day 14 of the
above graphs are also shown. Concentration response curves at day 14 for 17-AAG (d) and PI-103 (g) are shown. Values are means ± SD (n = 6).
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Page 11 of 20HN4, treated with PI-103 and 17-AAG, respectively
(Additional file 12).
KNS42, LICR-LON-HN4 and U-87 MG generate tight
spheroids, ideal for fully automated growth kinetic assays.
With spheroids of looser morphology, or where agents
cause dissociation of the three-dimensional structure, a
Celigo cytometer still provides fully automated imaging
but does not always provide accurate size determination.
Images can then be imported into Image-Pro Analyzer
software and manually manipulated for data analysis
(data not shown). Alternatively, if no cytometer is avail-
able, images can be obtained using an inverted micro-
scope and analyzed on Image-Pro Analyzer software. The
results obtained using both methods are highly compar-
able; thus the latter is a perfectly acceptable (lower
throughput) alternative. Two comparative examples are
shown in Additional file 13 for U-87 MG and LICR-
LON-HN4 spheroids treated with 17-AAG. Concentra-
tion-dependent inhibition trends are fully reproducible
between the two imaging/analysis systems as demon-
strated by a head-to-head comparison using LICR-LON-
HN4 (Additional files 12 and 13).
HSP90 and PLCg inhibitors prevent tumor dissemination on
matrix protein
The tumor spheroid-based migration assay (Figure 4a) was
adopted to mimic cell motility mediated by cell-substrate
interactions. We previously reported that PLCg1i si m p o r -
tant in integrin-mediated cell migration [37]. To exemplify
the power of the assay, we show here that an in-house
PLCg inhibitor (CCT130234) reduces the migration of
both U-87 MG and MDA-MB-231 tumor cells at sub-GI50
concentrations (Figure 7a-c and Table 2).
HSP90 is also involved in tumor cell migration through
client proteins including c-MET, SRC and FAK [35]. The
HSP90 inhibitor 17-AAG potently inhibited migration of
U-87 MG, KNS42 and MDA-MB-231 cells in a concentra-
tion-dependent manner as early as 24 h (Figure 7d-f and
T a b l e2 ) .T h ef a c tt h a ti n h i b i tory effects are manifest at
low concentrations and short time intervals is of particular
importance, indicating selective effects on tumor cell
migration at least partly independent of proliferation.
17-AAG inhibits three-dimensional tumor spheroid invasion
into Matrigel
Another aspect of tumor progression is the ability of cells
to invade basement membranes and connective tissue,
enabling escape from the primary tumor and, in some
cases, subsequent metastasis. U-87 MG glioma spheroids
(representing a locally invasive tumor type) were
embedded in Matrigel and treated with 17-AAG. Tumor
cell invasion was monitored up to 72 h, although effects
of the compound were apparent after just 24 h and inva-
sion was inhibited at sub-GI50 concentrations (Figure 8a,
b and Additional file 14a). A Celigo cytometer was used
for a fully automated image analysis (Figure 8a) and
representative images with the segmentation analysis
around the invading cells are shown in Figure 8b at the
24 h timepoint. Additionally, similar results are obtained
using the Celigo cytometer for automated imaging only,
with the analysis performed on Image-Pro Analyzer soft-
ware as an example of lower throughput (Additional file
14a). As indicated previously, a non-automated image
capture and analysis method (microscopy and Image-Pro
Analyzer software) can similarly be applied. This is illu-
strated by the inhibitory effects of 17-AAG on invasion
of spheroids formed by highly malignant MDA-MB-231
M (metastatic variant) triple negative breast cancer cells
(Additional file 14c).
Discussion
Building on the pioneering work of Friedrich et al. [26]
and others, here we demonstrate a novel method for the
rapid generation and quantitative analysis of tumor
spheroid growth in HT format, with additional applica-
tions in further important aspects of the malignant phe-
notype. The assays can readily be established in any
laboratory without specialized equipment and negate the
need to purchase preformed spheroids, which may only
be available for a limited number of cell lines. Although
the quantitation is significantly enhanced by the use of
automated cytometry, we have also deliberately exempli-
fied its utility using standard microscopy to broaden its
accessibility to the research community.
Recent advances in the development of three-dimen-
sional cultures for cancer drug evaluation have focused
mainly on methods that avoid cell surface adhesion and
promote cell-cell attachment [12,26,52]. Most are based
on cellular aggregation on agarose-coated flat-bottomed
plates [26,28], poly-Hema-coated round-bottomed or V-
bottomed plates [52] or hanging drops [25]. Although able
to generate reproducibly-sized spheroids, all such methods
rely on time-consuming procedures or the need to transfer
spheroids from delicate hanging drops to plates for further
analysis. More recently, advances in microtechnologies
have engineered plates for low binding of cells to the sur-
face [30].
In pilot studies we compared different techniques for
generating spheroids (bioreactor, agar-coated 96-well
plates, poly-Hema-coated plates). We found that the ULA
96-well round-bottomed plate method is the least time
consuming and generates the most reproducible spher-
oids. We have carried out a direct comparison with agar-
coated plates and demonstrated that the tumor spheroids
grown in ULA plates have equivalent growth rates, com-
parable gradients of proliferation and increased hypoxia in
older spheroids but in general present a more compact
and uniform structure. Also ULA plate-generated spher-
oids have the significant advantage that they are ideally
suited to automated image analysis using a Celigo
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Page 12 of 20Figure 7 CCT130234 and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) concentration-dependent inhibition of tumor
dissemination on matrix protein. (a-c) Day 4 U-87 MG and MDA-MB-231 P (parental variant) spheroids were placed on gelatin-coated plates
and treated with the phospholipase C (PLC)g inhibitor (CCT130234) over a range of concentrations. Controls were treated with vehicle. Images
were captured at intervals (from t0 to 72 h) using an inverted microscope and analyzed with Image-Pro Analyzer software. Representative results
of three separate experiments are shown for (a) U-87 MG and (b) MDA-MB-231 P. Values are means ± SD; (n = 12). Student t test with Welch’s
correction was performed relative to 72 h values: (a) vehicle control vs 2.5 to 10 μM P < 0.001; (b) vehicle control vs 2.5 to 10 μM P < 0.001. (c)
Representative images for both cell lines at 72 h are shown. Scale bar: 500 μm. (d) U-87 MG, (e) KNS42 and (f) MDA-MB-231 P spheroids were
treated with 17-AAG over a range of concentrations and the area of migration at 24 h post treatment quantified. Values are means ± SD; n = 6.
Student t test with Welch’s correction was performed: (d) vehicle control vs 0.1 to 2.5 μM P < 0.001; (e) vehicle control vs 0.2 μM* * P < 0.01, vs 1
and 5 μM P < 0.001; (f) vehicle control vs 0.7 to 2.8 μM P < 0.001. A representative example of three separate experiments is shown for each cell
line.
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extensions to key functional assays) represents an impor-
tant advancement towards the routine use of three-dimen-
sional cultures for preclinical oncology drug development.
HT three-dimensional growth assays must satisfy sev-
eral key requirements: large scale, speed, simplicity,
reproducibility and automation (both for set-up as well
as readouts and data analysis). Here, we demonstrate
that combining the use of ultra-low attachment round-
bottomed plates with a Celigo cytometer, it is possible
to utilize three-dimensional tumor spheroid assays in
drug discovery projects in HT format. Building on this
basic growth kinetic assay, we also successfully opti-
mized de novo three-dimensional tumor spheroid-based
functional assays in 96-well plates, for relatively HT for-
mats: in situ three-dimensional tumor spheroid invasion
into Matrigel, migration of cells from tumor spheroids
on matrix proteins (also enabling detailed phenotypic
analysis), and coculture of tumor spheroids with EBs
representing tissue invasion with reciprocal angiogenesis.
In contrast to previously reported invasion assays
[53,54], our method avoids the need to move spheroids
and allows true three-dimensional invasion rather than
superficial interactions between spheroids placed on top
of (or between) layers of matrix proteins. In the
complementary assays of cell migration and tissue inva-
sion/angiogenesis, preformed tumor spheroids are easily
and quickly transferred onto matrix-coated wells or into
coculture with EBs (uniformly generated using the same
ULA plates as for spheroids), in a single step using mul-
tichannel pipettes. Our methods significantly accelerate
and simplify the assays, but at the same time generate
highly reproducible results. Furthermore, they combine
real-time quantitative kinetic analyses with options for
more detailed morphological and molecular investiga-
tions: for example, qualitative determinations of modes
of cell motility; recovery of spheroids for genetic/pheno-
typic or pharmacodynamic analyses, target validation
using cells in which genes of interest are genetically
repressed or mutated.
The assays can easily be modified further according to
specific requirements: migration/haptotaxis on different
matrix proteins such as collagen, fibronectin, laminin,
on endothelial cell monolayers, or (for glioblastomas) on
recently described nanofiber scaffolds [15]: invasion into
alternative matrixes (for example, collagen) or, to avoid
animal tissue derivates, fully synthetic biopolymers;
microenvironment-enriched spheroids incorporating
endothelial cells, immune cells and/or stromal cells [10].
The current spheroid-EB coculture is designed to mimic
Figure 8 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) mediated concentration-dependent inhibition of tumor spheroid
invasion into Matrigel. (a, b) Day 4 U-87 MG spheroids were embedded into Matrigel for three-dimensional invasion. 17-AAG was used over a
range of concentrations and control spheroids were treated with vehicle. Automated image analysis was carried out at intervals from t0 to 72 h
on a Celigo cytometer using the Colony Counting Confluence application scanning 1/16 field of view/well. Invasion was normalized to t0. (a) A
representative example of three separate experiments is shown. Values are means ± SD; n = 8. Student t test with Welch’s correction was
performed relative to 72 h values: vehicle control vs 0.1 to 2.5 μM P < 0.001. (b) Representative images of U-87 MG spheroid invasion obtained
on a Celigo cytometer show the reproducibly sized spheroids at t0 and the typical segmentation around the invading cells with a clear
inhibition by the 17-AAG at 24 h (also seen at concentrations below the concentration inhibiting cell viability by 50% (GI50) for this cell line (see
Table 2)). Images of one field of view/well were cropped and magnified (20 ×) to allow visualization of the invasion. Scale bar: 500 μm.
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encountering mouse tissue/vasculature), the mainstay of
preclinical drug evaluation studies, but human ESCs
could be substituted to generate a fully human three-
dimensional confrontation culture system.
In addition to optimization and streamlining of spher-
oid generation and a suite of functional assays, we have
successfully automated imaging and quantitation of real-
time spheroid growth and also invasion using a Celigo
cytometer. We are currently developing further proto-
cols for fully automated imaging and analysis of the
migration and the coculture assays. These, together with
the tumor spheroid growth kinetic and viability assays
will allow a complete analytical package to bridge the
gap between simple two-dimensional proliferation assays
and in vivo studies. We are currently using these assays
in a number of target validation and cancer drug discov-
ery projects where our data suggest that they have the
ability to reflect in vivo activity. Once fully validated for
a wider range of agents and shown to have predictive
value for therapeutic efficacy, we believe such assays will
become a mainstay of the preclinical functional tumor
assay portfolio and reduce the need for extensive testing
in animal tumor models.
Conclusions
We provide a comprehensive suite of simple, reproduci-
ble three-dimensional tumor spheroid models that reca-
pitulate in vitro some of the key hallmarks of cancer
and that at the same time can provide a dynamic, auto-
mated, quantitative imaging and analysis compatible
with high-throughput preclinical studies. We provide
evidence that our methods have the potential to
enhance target selection through rapid functional
screening assays and the effective triaging of drug candi-
dates prior to in vivo studies.
Methods
Cell lines and culture conditions
For the majority of our studies, four tumor cell lines
representative of highly invasive cancers were selected:
glioblastoma (U-87 MG, KNS42); oral squamous cell
carcinoma (LICR-LON-HN4) and triple negative breast
carcinoma (MDA-MB-231). Additional cell lines were
included in spheroid formation trials to cover a wide
range of tumor types.
Tumor cell lines (Table 1) were grown in tissue cul-
ture flasks under standard conditions (37°C, 5% CO2,
95% humidity). All media (Table 1) were as recom-
mended by the supplier of the cells and were supple-
mented with 10% fetal calf serum (FCS), with the
exception of the DLD-1 medium that was additionally
supplemented with 1 × non-essential amino acids
(NEAA). Media were routinely changed twice weekly.
When subconfluent, cell monolayers were passaged
using TrypLE Express Phenol Red, (Gibco, Life Technol-
ogies Ltd. Paysley, UK).
mES R1 cells were grown on mitomycin-C treated
mouse embryonic fibroblast (MEF) feeder layers in ESC
medium: Dulbecco’s modified Eagle medium (DMEM)
(4.5 g/l D-glucose; sodium pyruvate), supplemented with
15% FCS, 1 × penicillin, streptomycin and neomycin
antibiotic mix (Gibco, Life Technologies Ltd. Paysley,
UK), 100 μM b-mercaptoethanol (Sigma-Aldrich Com-
pany Ltd., Dorset, England), 1 × NEAA plus 1,000 U/ml
leukemia inhibitor factor (LIF). Medium was changed 24
h after seeding (1.4 × 10
5 cells/ml, 5 ml/60 mm dish)
and cells were passaged 2 to 3 days later. All media and
NEAA were purchased from Gibco (Life Technologies
Ltd. Paysley, UK), and FCS from Biosera.
Generation and analysis of tumor spheroids
For spheroid generation, 200 μl/well of cell suspensions
at optimized densities (0.5 × 10
4 cells/ml for U-87 MG,
KNS42 and LICR-LON-HN4; 1.5 × 10
4 for MDA-MB-
231 P and M variants) were dispensed into ULA 96-well
round-bottomed plates (Corning B.V. Life Sciences,
Amsterdam, The Netherlands) using a multichannel pip-
ette. Plates were incubated for 4 days at 37°C, 5% CO2,
95% humidity. Where indicated, optimal three-dimen-
sional structures were achieved by addition of 2.5%
Matrigel as previously described [52]. Fully automated
image analysis of tumor spheroids was carried out on a
Celigo cytometer (Cyntellect Inc, San Diego, CA, USA;
http://www.cyntellect.com/content/products/celigo/
index.html), which is equipped with a 4-megapixel CCD
camera with an F-theta scan lens (1 μm/pixel, 0.25 NA,
3.5 ×). Images were acquired and analyzed by using the
Colony Counting Embryoid Body application with the
option to scan 1/16 field of view/well. The width of 1
field of view (FOV) is 975 pixels/2,057 μma n di m a g e
file size is 0.41 MB. Further technical details of imaging
parameters are shown in Additional file 15.
For the lower throughput method, images were cap-
tured using an inverted microscope (Olympus IX 70,
(Olympus Microscopy, Southend-on-SeaEssex, UK)
equipped with a CCD camera (QImaging, Surrey, BC,
Canada and imported into Image-Pro Plus Analyzer
software (Media Cybernetics, Inc., Bethesda, MD, USA;
http://www.mediacy.com/index.aspx?page=IPP) and by
either using macros or manually, multiparametric analy-
sis was performed. In both cases, the radius of each
tumor spheroid was used to calculate the volume (μm
3):
V = 4/3 π r
3.
For comparison with our system, U-87 MG cells were
also used to generate spheroids using conventional
methods as follows: (1) agar-coated 96-well flat-bot-
tomed plates (BD Biosciences, Oxford, England) as
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4 cells/ml as in the
ULA 96-well round-bottomed plates); (2) poly-Hema-
coated 24-well plates (2 × 10
5 cells/ml, 1 ml/well). A
stock solution of 6 mg/ml poly-Hema (Sigma-Aldrich
Company Ltd., Dorset, England) in 95% ethanol was
prepared and diluted 1:10 in ethanol. A total of 100 μl/
well was dispensed and left to dry before cell addition;
(3) RCCS (10
5 cells/ml, 10 ml/disposable vessel).
In all cases, an inverted microscope was used for
image analysis as described above.
Tumor spheroid growth kinetics and treatment with test
compounds
Spheroids were generated as described above. Growth
kinetics and inhibition assays were performed as pre-
viously reported [26] but with significant modifications.
Briefly, spheroid size was measured up to 14 days after
initiation. A 50% medium replenishment was performed
on days 4, 7, 10 and 12 using a multichannel pipette.
Image analysis was performed on a Celigo cytometer or
by microscopy as described. Where indicated, day 4
tumor spheroids were treated with 17-AAG (Invivogen,
San Diego, CA, USA), or PI-103 (Charnwood Molecular
Ltd., Loughborough, UK). Control spheroids were trea-
ted with appropriate vehicle. Then, 72 h following com-
pound addition, 50% medium replenishment was
performed as described above. Responses were evaluated
by spheroid volume measurements at regular intervals.
Tumor spheroid-based migration assay on matrix protein
Flat-bottomed, 96-well plates (Corning B.V. Life
Sciences, Amsterdam, The Netherlands) were coated
with 0.1% (v/v) gelatin (Sigma-Aldrich Company Ltd.,
Dorset, England) in sterile water for 1 h at 37°C. A total
of 200 μl/well of culture medium supplemented with 2%
(v/v) FCS was then added. For compound evaluation
studies, medium contained 1.5 × the final concentration
of 17-AAG or PLCg inhibitor CCT130234, in a dilution
series. Controls were treated with vehicle.
A total of 100 μl medium was removed from each well
containing 4-day spheroids, and the remaining medium
including the spheroids transferred into the prepared
‘migration’ plate using a multichannel pipette (final
volume 300 μl). Spheroids were allowed to adhere and
images were obtained at t0, 24, 48 and 72 h, using an
inverted microscope as described. Effects of compounds
were analyzed by measuring the area covered by migrat-
ing cells using Image-Pro Analyzer software to track the
migration front. Data were normalized to the initial size
of each spheroid at t0. For timelapse experiments,
images were recorded every 15 minutes over a period of
70 h and videos edited using AVS Video Editor (Online
Media Technologies Ltd., London, Uk).
Tumor spheroid-based Matrigel invasion assay
A total of 100 μl medium was removed from wells con-
taining 4-day spheroids and 100 μlM a t r i g e lw a sg e n t l y
added. When Matrigel solidified, 100 μl of culture med-
ium was added on top. For compound evaluation stu-
dies, 17-AAG or vehicle was added to both the Matrigel
and the overlying medium. U-87 MG spheroids were
treated on the day of assay initiation while MDA-MB-
231 spheroids were pretreated for 24 h and during the
assay. From t0 and at intervals up to 72 h, automated
image analysis was carried out for U-87 MG on a Celigo
cytometer, using the Cell Counting Confluence applica-
tion. Due to the central location of the spheroid in each
well, only 1/16 of the field of view needed to be imaged.
The width for 1 FOV is 1,958 pixels/2,055 μma n d
image file size is 1.55 MB. A segmentation analysis
around the invading cells was produced and invasion
measured as the area covered by the invading cells (per-
centage confluence) in the scanned field of view. Analy-
sis settings must be adjusted for each cell type in order
to achieve an optimal image segmentation that also
reflects the degree of invasion. Alternatively, images
were imported and analyzed on Image-Pro Analyzer
software as described above. Finally, to demonstrate that
equivalent data can be generated in the absence of a
sophisticated cytometer, microscopic imaging and analy-
sis on Image-Pro Analyzer software was performed
using MDA-MB-231 M cells. Further technical specifi-
cations for both imaging methods are provided in Addi-
tional file 15.
EB differentiation and tumor spheroid-EB confrontation
culture
EB formation and cell differentiation was performed as
described [50] with some modifications. R1 cells (1 to 5
×1 0
3 cells/ml) in ESC medium containing 50 ng/ml
vascular endothelial growth factor (VEGF) (Sigma-
Aldrich Company Ltd., Dorset, England) were plated in
ULA 96-well round-bottomed plates, 200 μl/well. A 50%
medium refresh was performed daily from day 3 to day
14. Automated image analysis was performed using a
Celigo cytometer as described and growth curves were
generated.
For confrontation culture experiments [21], day 4
tumor spheroids and day 5 to day 7 EBs were used.
Using a multichannel pipette, 100 μl of culture medium
was removed from each well of the spheroid plate and
replaced with 100 μl of ESC medium. This procedure
was repeated three times, and after the last wash,
remaining medium containing a single spheroid/well
was transferred into the EB ULA plate to give a final
volume of 200 μl/well, with one spheroid and one EB in
each well. Confrontation cultures were incubated at
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targeted agent, cocultures were treated with 17-AAG (5
μM) or with vehicle (control). For timelapse studies,
videos were acquired on the Olympus microscope as
described above. Images were recorded hourly over 65
h. Where indicated, GFP-transduced U-87 MG tumor
spheroids were used and brightfield and fluorescence
images of the confrontation cultures were obtained over
55 to 60 h on a Celigo cytometer, using the Expression
Analysis application with the option to scan 1/16 field
of view/well.
Determination of coefficient of variation (CV) and
frequency distribution of tumor spheroid size
During assay optimization, the reproducibility of spher-
oid size was measured for U-87 MG, KNS42 and LICR-
LON-HN4 cells by determining their volumes on day 4.
The intraplate and interplate CV for each cell line was
calculated in at least three separate experiments over
three different batches ofp l a t e s .T h ef r e q u e n c yo f
spheroid volumes was plotted to illustrate Gaussian dis-
tribution of the sample for U-87 MG spheroids on day
4 (untreated) and on day 14 (controls and compound
treated) in a representative growth kinetic study.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Lumi-
nescent Cell viability assay (Promega, Madison, WI,
U S A ) .I np i l o ts t u d i e st od e t ermine optimal incubation
times, day 4 U-87 MG spheroids were incubated for 10,
30 and 60 minutes with CellTiter Glo reagents; all gave
comparable results, hence a 10 minute incubation time
was adopted for later studies. U-87 MG, KNS42, MDA-
MB-231 and LICR-LON-HN4 spheroids were established
as described. For cell monolayers (two-dimensional), cells
were plated into 96-well black-sided flat-bottomed plates
(Corning B.V. Life Sciences, Amsterdam, The Nether-
lands) at the following densities: 600 cells/well (U-87
MG, KNS42); 2,000 cells/well (MDA-MB-231) and 3,000
cells/well (LICR-LON-HN4). The outer wells of the
plates were filled with phosphate-buffered saline (PBS) to
reduce the effects of evaporation. Then, 4 days later,
three-dimensional and two-dimensional cultures were
treated with a range of concentrations of 17-AAG, PI-
103, CCT130234 or appropriate vehicle. Cultures were
incubated for 72 h and the CellTiter-Glo assay kit was
used following the manufacturer’s instructions. After 10
minutes of incubation with the CellTiter-Glo reagent,
three-dimensional cultures were pipette mixed, aspirated
with multichannel pipettes and transferred into black-
sided, flat-bottomed plates (Corning B.V. Life Sciences,
Amsterdam, The Netherlands) for luminescence mea-
surement on a Synergy 2 SL Luminescence microplate
reader (BioTek, Potton, UK) to generate GI50 values.
Immunohistochemistry
Tumor spheroids (TSs), EBs and TS-EB cocultures were
processed for immunohistochemistry as follows. Three-
dimensional structures were collected in V-bottomed 15
ml Falcon tubes and allowed to sediment. Supernatant
was removed by gentle aspiration and pellets washed
once with PBS. After repeated sedimentation, superna-
tant was removed and 4% paraformaldehyde (PFA) was
added and left overnight. The next day, PFA was
removed and, using a warmed p1000 pipette tip, 1 ml of
liquid agarose (4% w/v in sterile water) was gently
added to the three-dimensional structures that were
then collected and transferred into Tissue-Tek
®Cryo-
molds
® (Sakura Finetek UK Ltd., Thatcham, UK). Solidi-
fied blocks were transferred into 50% ethanol for 1 h
and then 80% ethanol before embedding in paraffin.
Sections of 4 μm were cut using a semiautomated
microtome HM 350 S (Microm International GmbH,
Walldorf, Germany); the tissue sections were deparaffi-
nized and rehydrated in water. Immunohistochemistry
was performed as previously described [55] and sections
were stained for Ki67 (monoclonal antibody, clone
MIB1, Dako UK Ltd., Ely, UK), GLUT-1 (no. 07-1401,
Millipore UK Ltd., London, UK) and CD34 (monoclonal
antibody, clone MEC14.7, Abcam, Cambridge, UK).
Slides were counterstained with hematoxylin and eosin
and coverslipped with DPX mountant for microscopy
(VWR Int., Lutterworth, UK).
Statistical analyses
The Student t test with Welch’s correction was performed
where indicated using Prism5( G r a p h p a dS o f t w a r e ,L a
Jolla, CA, USA; http://www.graphpad.com/welcome.htm).
Values are expressed as means ± SD. P values ≤ 0.05 were
considered statistically significant. For correlations
between spheroid size (volume) and luminescent signal as
well as for spheroid size and number of viable cells, Spear-
man correlation analysis was performed.
Additional material
Additional file 1: Classification of three-dimensional tumor spheroid
morphology. Representative examples are shown: (a) SF188: tight
spheroid; (b) MDA-MB-231 P: compact aggregate; (c) IGROV-1: loose
aggregate; (d) IGROV-1 compact aggregate upon Matrigel addition. Scale
bar: 200 μm.
Additional file 2: Generation of tumor spheroids: comparative
methods. U-87 MG spheroids were generated in (a) U-bottomed 96-well
ultra-low attachment (ULA) plates, (b) flat-bottomed 96-well agar-coated
plates, (c) 24-well poly-Hema-coated plates and (d) in a Rotary Cell
Culture System (RCCS; Cellon). In (a) and (b) one spheroid/well was
obtained with a tighter structure in the former. In (c) and (d) multiple
variably-sized spheroids were formed. All the images were taken 4 days
post initiation. Scale bar: 200 μm.
Additional file 3: Glioblastoma spheroid-based migration on gelatin.
Day 4 U-87 MG or KNS42 tumor spheroids were transferred onto a
gelatin-coated 96-well flat-bottomed plate (a single spheroid per well)
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time lapse study illustrate fast, dispersed migration for U-87 MG and a
slower radial, collective migration for KNS42. Images were obtained by
microscopy as described in methods section. Scale bar: 200 μm.
Additional file 4: Video 1. Glioblastoma spheroid-based migration on
gelatin. The video shows side by side the differential migration patterns
that characterize two glioblastoma cell lines (U-87 MG, adult and KNS42,
pediatric). Images were obtained every 15 minutes over a period of 70 h,
on an inverted microscope, Olympus IX 70, equipped with a Q Imaging
CCD camera. Videos were edited using AVS Video Editor from Online
Media Technologies Ltd. File format: MPEG.
Additional file 5: Video 2. Tumor spheroid (TS)-embryoid body (EB)
confrontation culture assay. Single day 4 U-87 MG TS and day 5 EBs were
cocultured in each well of ultra-low attachment (ULA) 96-well plates.
Timelapse imaging of the TS-EB confrontation culture shows the
relatively rapid attachment and coalescence of the two tissues. Images
were obtained on an inverted microscope every hour, over a period of
60 h. The video was edited as described above. File format: MPEG.
Additional file 6: Video 3. Tumor spheroid (TS)-embryoid body (EB)
confrontation culture assay. 17-N-Allylamino-17-demethoxygeldanamycin
(17-AAG) inhibits U-87 MG tissue invasion. Single day 4 green fluorescent
protein (GFP) transduced U-87 MG TS and day 7 EBs were cocultured in
each well of ultra-low attachment (ULA) 96-well plates. Cocultures were
treated with 17-AAG (5 μM) or with vehicle (control) at the initiation of
the cocultures. Timelapse imaging shows the invasion of U-87 MG GFP
cells towards the EB in the control coculture while no invasion is evident
in the 17-AAG treated culture. Images were obtained as described above
over a period of 40 h. File format: MPEG.
Additional file 7: Immunostaining of tumor spheroid (TS)-embryoid
body (EB) at the end of a confrontation culture assay (60 h).
Hematoxylin and eosin (H&E) staining (upper panel) shows the two
tissues and their close association. CD34 immunoperoxidase staining
(lower panel) identifies endothelial differentiation within the EB and the
extension of the pseudovascular structures into the TS (arrows). Scale
bars: 200 μm (left) and 100 μm (right) images.
Additional file 8: CellTiter Glo luminescent cell viability assay
validation for three-dimensional cultures. (a) CellTiter Glo assay of day
4 U-87 MG spheroids incubated for 10, 30 or 60 minutes with CellTiter
Glo reagents showed close comparability of the luminescent signals. (b)
Ultra-low attachment (ULA) plate generated U-87 MG spheroids were
imaged and used in a CellTiter Glo luminescent assay on days 3, 4, 5, 6,
8 and 11 post initiation. Spheroid volumes (μm
3) and luminescent counts
showed a significant positive correlation (Spearman rank). (c) U-87 MG
spheroids were initiated in ULA plates at different cell densities (5 × 10
4,
2.5 × 10
4, 12.5 × 10
4, 6.25 × 10
4 and 3.12 × 10
4 cell/well). Then, 4 days
later, spheroids were imaged and analyzed on a Celigo cytometer.
Representative images of three of the cultures are shown. Scale bar: 500
μm. Following imaging, spheroids were subjected to a CellTiter Glo
luminescent viability assay (d). For assessment of the relationship
between the number of viable cells and the luminescent signals from
spheroids, a standard curve was generated. A single cell suspension of U-
87 MG was plated into a 96-well plate, over a range of cell densities (10
5,
10
4,1 0
3 and 10
2 cells/well) and immediately subjected to a CellTiter Glo
assay alongside the spheroids (e). Volumes (μm
3) and the number of
viable cells per spheroid determined using the standard curve showed a
significant positive correlation (Spearman rank). Values are shown as
means ± SD, n = 8.
Additional file 9: Scatter plots of the concentration inhibiting cell
viability by 50% (GI50) values for cell viability studies summarized
in Table 2. (a-c) U-87 MG, KNS42, LICR-LON-HN4 and MDA-MB-231 (P
and M) cells were grown in two dimensions (monolayer) and in three
dimensions (spheroids). Then, 4 days later, cells were treated with (a) 17-
N-allylamino-17-demethoxygeldanamycin (17-AAG) (final concentrations 0
to 100 μM for U-87 MG and KNS42, 0 to 25 μM for MDA-MB-231 P and
M, 0 to 1 μM for LICR-LON-HN4), (b) PI-103 (final concentrations 0 to 25
μM for U-87 MG and KNS42) and (c) CCT130234 (final concentrations 0
to 100 μM for U-87 MG and MDA-MB-231 P). Then, 72 h later, a CellTiter
Glo luminescence assay for cell viability was performed and GI50 values
were determined. Dots represent GI50 values from each assay and means
± SD are plotted.
Additional file 10: Comparison of sensitivity to compounds in two-
dimensional vs three-dimensional cultures. (a, b) MDA-MB-231 P cells
were grown in two dimensions (monolayer) and in three dimensions
(spheroids). Then, 4 days later, cells were treated with (a) 17-N-allylamino-
17-demethoxygeldanamycin (17-AAG) (final concentrations 0 to 25 μM)
or (b) CCT130234 (final concentrations 0 to 100 μM). Then, 72 h later, a
CellTiter Glo luminescence assay for cell viability was performed and
concentration inhibiting cell viability by 50% (GI50) values were
determined. Values are means ± SD, n = 6; (a) and (b) are representative
of three separate experiments.
Additional file 11: Volume distribution of control and treated U-87
MG spheroids. Frequency plots of volume (μm
3 ×1 0
7) distribution for
controls (vehicle) and PI-103 treated (0.5 μM and 0.06 μM) U-87 MG
spheroids on day 14 of a growth kinetic assay (n = 18). One example of
three replicate studies (n = 6) is shown in Figure 6e.
Additional file 12: PI-103 and 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) concentration-dependent
inhibition of tumor spheroid growth kinetics: fully automated
imaging and analysis. (a) KNS42 and (b) LICR-LON-HN4 spheroids were
treated on day 4 as described above, with PI-103 (0 to 2 μM) and 17-
AAG (0 to 2.93 μM) respectively, accordingly to their three-dimensional
concentration inhibiting cell viability by 50% (GI50) values (see Table 2). A
Celigo cytometer was used for automated imaging and analysis. Graphs
show concentration-dependent inhibition of spheroid growth from day 4
to day 14. Values are means ± SD, n = 6; one representative of three
separate experiments is shown.
Additional file 13: 17-N-Allylamino-17-demethoxygeldanamycin (17-
AAG) concentration-dependent inhibition of tumor spheroid
growth kinetics: alternative non-automated analysis. (a) U-87 MG
and (b) LICR-LON-HN4 spheroids were treated on day 4 with 17-AAG (0
to 2 μM for U-87 MG and 0 to 2.93 μM for LICR-LON-HN4), according to
their three-dimensional concentration inhibiting cell viability by 50%
(GI50) values (see Table 2). Images were obtained by microscopy as
described above and analysis of spheroid growth was performed using
Image-Pro Analyzer software. Graphs show a concentration-dependent
growth inhibition of the spheroids from day 4 to day 14. Values are
means ± SD, n = 6; one representative of three separate experiments is
shown for each cell line.
Additional file 14: 17-N-Allylamino-17-demethoxygeldanamycin (17-
AAG) mediated concentration-dependent inhibition of tumor
spheroid invasion into Matrigel. (a-d) day 4 U-87 MG or MDA-MB-231
M (metastatic variant) spheroids were embedded into Matrigel for three-
dimensional invasion. 17-AAG was used over a range of concentrations
and control spheroids were treated with vehicle. Images were captured
at intervals from t0 to 72 h using a Celigo cytometer for U-87 MG or an
inverted microscope for MDA-MB-231 M. The area of invasion was
determined using Image-Pro Analyzer software. Representative examples
of three separate experiments are shown for U-87 MG (a, b) and for
MDA-MB-231 M (c, d). Values are means ± SD, n = 6. (b, d)
Representative images of spheroid invasion were obtained on a Celigo
cytometer (b) or by microscopy (d) at t0 and 24 h. Scale bar: 500 μm.
Additional file 15: Imaging parameters: Celigo cytometer and
microscopy. Technical details.
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